This is Gul Rahim’s story of typhoid, as told to Attaullah Baig of Aga Khan University Hospital on January 7, 2017, and translated into English. The interview was conducted in Urdu and has been edited for clarity and length.

More than 300 researchers from 45 countries gathered in Kampala, Uganda in early April for the 10th International Conference on Typhoid and Other Invasive Salmonelloses.

When the 70th World Health Assembly (WHA) begins today in Geneva, Switzerland, it will be one of historic measure. Not only because the WHA be electing a new Director-General of the World Health Organization (WHO), but also because of its sheer scope.

Early on a beautiful spring morning in the nation’s capital, a group of Georgetown University undergraduates gathered on the corner of First Street and Constitution Avenue, far from their textbooks and thoughts of their looming final exams. Their unusual study break? A day of meetings with congressional offices to advocate against cuts to critical U.S. government funding for global health.
For years, little was known of the typhoid burden in Africa, even though outbreaks of multi-drug resistant typhoid is becoming increasingly common. This lack of information spurred the Bill and Melinda Gates Foundation to fund the Typhoid Fever Surveillance in Africa Program (TSAP) through the International Vaccine Institute, a first-of-its-kind study established to shed light on true extent of the typhoid burden and multi-drug resistance distribution on the continent. The results from the TSAP, recently published in the Lancet Global Health, represent the most comprehensive and rigorous analysis of typhoid in Africa and could change our understanding of the disease burden across the continent.

Vaccines are healthcare’s first line of defense. From polio to pertussis, rubella to rotavirus, vaccination has saved more lives than any other medical advance in recent history.

Global health research and development has a multiplier effect. It not only saves and improves lives, but also creates cost savings, drives economic growth and enhances global security.

Last night, Dr. Jan Holmgren received the 24th annual Albert B. Sabin Gold Medal Award in honor of his pioneering work in mucosal immunology and leadership in the development the world’s first oral cholera vaccine. Guests gathered at the National Academy of Sciences building in Washington, D.C., under a mural of Prometheus inscribed “hearken to the miseries that beset mankind” – a fitting setting for the celebration of a career spent fighting an ancient disease of the poor.
Every year, the Albert B. Sabin Gold Medal Award is given to a distinguished member of the public health community who has made extraordinary contributions in the field of vaccinology. This year's award will honor Jan Holmgren, M.D., Ph.D., for his pioneering contributions to oral vaccine research and mucosal immunology, as well as his leadership in the discovery of the world's first effective oral cholera vaccine.
Overseas travelers can sometimes bring back unwanted souvenirs — with tragic consequences. A localized outbreak of typhoid in Auckland, New Zealand has taken the life of one patient and affected 20 others. Public health authorities believe that a traveler to a typhoid-endemic country may have unknowingly contracted the disease and carried it back into the country.

Pages